Trends in diagnostic nuclear medicine in Sweden (2008–2023): utilisation, radiation dose, and methodological insights

PET procedures are increasing in scope and now constitute the largest contribution to radiation dose, and in-house production of PET radiopharmaceuticals is available in around 40% of clinics. The number of radionuclides decreased over the study period, and GC procedures declined. In general, the amount of administered activity remained stable over the period for the procedures studied. Accurately assessing utilisation and exposure trends requires extensive data, and the methodology used affects the result significantly.